fentiazac
Sign in to saveAlso known as Fentiazaco, Fentiazacum, 4-(p-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid, 4-(4-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid
Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain. Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.
Research
58 papers- Fentiazac in the treatment of osteoarthritis and tendinitis.Current medical research and opinion · 1983
- Metabolism of fentiazac.Arzneimittel-Forschung · 1980
- Fentiazac in rheumatoid arthritis: comparison with sulindac and long-term tolerance.Current medical research and opinion · 1983
- Fentiazac as a therapeutic aid in the treatment of tuberculosis.The Journal of international medical research · 1977
- Fentiazac in osteoarthritis: comparison of BID and QID regimens.Clinical therapeutics · 1983
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain. Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.
Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.
Excerpted from Wikipedia’s “fentiazac” article, available under the CC BY-SA 4.0 licence.
Available in 7 languages
via Wikidata sitelinks · CC0